PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
23.23%
Revenue growth at 75-90% of META's 30.75%. Bill Ackman would push for innovation or market expansion to catch up.
23.00%
Gross profit growth at 50-75% of META's 32.33%. Martin Whitman would question if cost structure or brand is lagging.
39.58%
EBIT growth 50-75% of META's 58.89%. Martin Whitman would suspect suboptimal resource allocation.
39.58%
Operating income growth at 50-75% of META's 58.89%. Martin Whitman would doubt the firm’s ability to compete efficiently.
35.39%
Net income growth at 75-90% of META's 42.99%. Bill Ackman would press for improvements to catch or surpass competitor performance.
36.14%
EPS growth at 75-90% of META's 43.27%. Bill Ackman would push for improved profitability or share repurchases to catch up.
36.59%
Diluted EPS growth at 75-90% of META's 43.17%. Bill Ackman would expect further improvements in net income or share count reduction.
-0.57%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.42%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
33.37%
OCF growth at 75-90% of META's 42.86%. Bill Ackman would demand better working capital management or cost discipline.
48.30%
FCF growth similar to META's 53.56%. Walter Schloss would attribute it to parallel capital spending and operational models.
538.53%
10Y revenue/share CAGR under 50% of META's 2009.31%. Michael Burry would suspect a lasting competitive disadvantage.
171.50%
5Y revenue/share CAGR under 50% of META's 376.46%. Michael Burry would suspect a significant competitive gap or product weakness.
80.89%
3Y revenue/share CAGR at 50-75% of META's 121.15%. Martin Whitman would question if the firm lags behind competitor innovations.
509.16%
10Y OCF/share CAGR under 50% of META's 2239.52%. Michael Burry would worry about a persistent underperformance in cash creation.
259.77%
5Y OCF/share CAGR at 50-75% of META's 392.36%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
126.95%
3Y OCF/share CAGR 1.25-1.5x META's 87.06%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
467.15%
Below 50% of META's 3057.02%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
214.79%
Below 50% of META's 615.72%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
618.14%
3Y net income/share CAGR above 1.5x META's 168.62%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
355.85%
Below 50% of META's 2125.44%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
88.22%
Below 50% of META's 187.63%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
49.96%
3Y equity/share CAGR at 50-75% of META's 76.34%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while META invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
23.01%
AR growth well above META's 41.26%. Michael Burry fears inflated revenue or higher default risk in the near future.
-12.81%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.81%
Asset growth at 75-90% of META's 8.79%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
5.12%
50-75% of META's 9.01%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
0.77%
Debt growth far above META's 0.36%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
2.42%
R&D dropping or stable vs. META's 9.34%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
16.57%
SG&A growth well above META's 9.08%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.